3-((1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-3-yl)methyl)benzoic acid | 1352993-39-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-((1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-3-yl)methyl)benzoic acid
• 英文别名: Trazpiroben；3-[[1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-3-yl]methyl]benzoic acid
• CAS: 1352993-39-5
• 化学式: C₃₁H₃₉N₃O₄
• 分子量: 517.668
• InChiKey: BDXJYAAYLZTLEK-UHFFFAOYSA-N

物化性质

• 沸点：
  733.0±60.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)
• pKa：
  4.18±0.10 (Predicted,Most Acidic Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  38
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  81.2
• 氢给体数：
  1
• 氢受体数：
  6

制备方法与用途

曲唑吡罗本（TAK-906）是一种多巴胺D2/D3受体拮抗剂，主要用于治疗中重度胃轻瘫的慢性症状。

文献信息

• [EN] D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE<br/>[FR] ANTAGONISTES D2, PROCÉDÉS DE SYNTHÈSE ET MÉTHODES D'UTILISATION
  申请人：ALTOS THERAPEUTICS LLC

  公开号：WO2011160084A1

  公开（公告）日：2011-12-22

  Provided are D2 or D3 antagonist compounds and pharmaceutical compositions of formula I and pharmaceutically acceptable salts thereof, or isomers thereof, wherein R1, R2 and R3 are as defined herein. The invention further comprises methods for making the compounds of the invention and methods for the treatment of conditions mediated by the dopamine D2 or D3 receptor from the compounds of the invention.

  提供了D2或D3拮抗剂化合物以及公式I和其药学上可接受的盐或异构体的药物组合物，其中R1、R2和R3如本文所定义。该发明还包括制备该发明化合物的方法以及利用该发明化合物治疗由多巴胺D2或D3受体介导的疾病的方法。
• D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE
  申请人：Luehr Gary W.

  公开号：US20120010228A1

  公开（公告）日：2012-01-12

  Provided are D 2 or D 3 antagonist compounds and pharmaceutical compositions of formula I and pharmaceutically acceptable salts thereof, or isomers thereof, wherein R 1 , R 2 and R 3 are as defined herein. The invention further comprises methods for making the compounds of the invention and methods for the treatment of conditions mediated by the dopamine D 2 or D 3 receptor from the compounds of the invention.

  提供了D2或D3拮抗剂化合物及其制备方法，以及公式I的制药组合物及其药学上可接受的盐或同分异构体，其中R1、R2和R3如本文所定义。本发明还涉及制备本发明化合物的方法，以及利用本发明化合物治疗由多巴胺D2或D3受体介导的疾病的方法。
• Treatment of gastroparesis with triazaspiro[4.5]decanone
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US11202776B2

  公开（公告）日：2021-12-21

  Provided herein is a method of treating or alleviating one or more symptoms of a disorder, disease, or condition mediated by a dopamine D2 or D3 receptor with 3-((1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-3-yl)methyl)benzoic acid or a pharmaceutically acceptable salt thereof. Also provided herein is a method of increasing the serum prolactin level with 3-((1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-3-yl)methyl)benzoic acid or a pharmaceutically acceptable salt thereof.

  本文提供了一种用3-((1-环己基-4-氧代-8-(4-氧代-4-苯基丁基)-1,3,8-三氮杂螺[4.5]癸烷-3-基)甲基)苯甲酸或其药学上可接受的盐治疗或减轻由多巴胺D2或D3受体介导的紊乱、疾病或病症的一种或多种症状的方法。本文还提供了一种用 3-((1-环己基-4-氧代-8-(4-氧代-4-苯基丁基)-1,3,8-三氮杂螺[4.5]癸烷-3-基)甲基)苯甲酸或其药学上可接受的盐提高血清催乳素水平的方法。
• TREATMENT OF GASTROPARESIS WITH TRIAZASPIRO(4.5)DECANONE
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：EP3621618A1

  公开（公告）日：2020-03-18
• TREATMENT OF GASTROPARESIS WITH TRIAZASPIRO[4.5]DECANONE
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20200155523A1

  公开（公告）日：2020-05-21

  Provided herein is a method of treating or alleviating one or more symptoms of a disorder, disease, or condition mediated by a dopamine D 2 or D 3 receptor with 3-((1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro[4.5]de-can-3-yl)methyl)benzoic acid or a pharmaceutically acceptable salt thereof. Also provided herein is a method of increasing the serum prolactin level with 3-((1-cyclohexyl-4-oxo-8-(4-oxo-4-phenylbutyl)-1,3,8-triazaspiro[4.5]decan-3-yl)methyl)benzoic acid or a pharmaceutically acceptable salt thereof.